POTASSIUM ACETATE INJECTION USP 39.2 %
POTASSIUM ACETATE : 39.2 % · DIN 02362597 · OMEGA LABORATORIES LIMITED
Health Canada status: MARKETED
What is POTASSIUM ACETATE INJECTION USP?
POTASSIUM ACETATE INJECTION USP 39.2 % contains POTASSIUM ACETATE : 39.2 %. It is listed in the Health Canada Drug Product Database under DIN 02362597, held by OMEGA LABORATORIES LIMITED, supplied as LIQUID for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 10-Oct-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is POTASSIUM ACETATE INJECTION USP used for?
Replacement and maintenance of normokalemia when a source of acetate is also required or when potassium chloride cannot be used.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02362597 |
|---|---|
| Brand name | POTASSIUM ACETATE INJECTION USP |
| Generic / active ingredient | POTASSIUM ACETATE : 39.2 % |
| Manufacturer | OMEGA LABORATORIES LIMITED |
| Strength | 39.2 % |
| Dosage form | LIQUID |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B05XA17 POTASSIUM ACETATE |
| AHFS class | 40:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 10-Oct-2025 |
| Original market date | 2016-07-18 00:00:00 |
How is it administered?
Administered i.v. only after dilution. Dose and rate depend on patient needs. Monitor ECG and serum potassium. Not for direct injection. Use immediately after dilution.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 15 and 30°C. Do not freeze.
How is it supplied?
Boxes of 10 vials x 50 mL. Flip-top vials. Stopper not made with natural rubber latex.
Contraindications
Hyperkalemia; diseases or conditions that predispose to hyperkalemia.
Warnings and precautions
Must be diluted. High/low potassium is toxic. Infusion rate >10 mmol/hour requires cardiac monitoring. Caution in cardiac/renal disease and metabolic/respiratory alkalosis.
Is POTASSIUM ACETATE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code B05XA17 POTASSIUM ACETATE. 1 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| POTASSIUM ACETATE | 392 MG | LIQUID | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | DIN 00780650 |
| POTASSIUM ACETATE INJ 2MEQ/ML | 2 mEq | SOLUTION | ABBOTT LABORATORIES, LIMITED | CANCELLED POST MARKET | DIN 00613444 |
| POTASSIUM ACETATE INJ 392MG/ML USP | 392 MG | LIQUID | LYPHOMED, DIVISION OF FUJISAWA CANADA INC. | CANCELLED POST MARKET | DIN 01944894 |
| POTASSIUM ACETATE INJECTION | 392 MG | SOLUTION | FRESENIUS KABI CANADA LTD | DORMANT | DIN 02139553 |
Who else supplies POTASSIUM ACETATE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. POTASSIUM ACETATE appears in 158 registered pack listings across 8 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.